
Opinion|Videos|June 5, 2025
Patient Conversation and Adoption of CSAI in Clinical Practice
Panelists discuss how comprehensive education and training resources are essential for clinicians, patients, and caregivers to successfully implement continuous subcutaneous infusion systems in Parkinson disease management.
Advertisement
Episodes in this series

Video content above is prompted by the following:
Education and Resources for Adoption
Clinician Education Needs:
- Hands-on training with infusion systems
- Protocol development for patient selection and monitoring
- Management of common adverse events
- Dosing algorithms and titration strategies
- Reimbursement and access navigation
- Interpretation of continuous monitoring data
Patient/Caregiver Education Needs:
- Device operation and maintenance
- Recognition and reporting of adverse events
- Troubleshooting common technical issues
- Understanding medication action timing
- Symptom tracking and diary maintenance
- Skin care at infusion sites
- When and how to seek medical assistance
- Setting realistic expectations about benefits and limitations
Advertisement
Related to this article

Benjamin Walter, MD, MBA, discusses how advances in biomarker testing and genetic characterization are informing Parkinson disease care, alongside developments in adaptive deep brain stimulation and efforts to identify disease earlier.

Late-breaking findings from MDS 2026 suggest a gluten-free diet may affect cognitive and quality-of-life measures in Parkinson disease, although no significant changes in motor function were observed.

Exploratory extracellular vesicle biomarkers suggested KP405, a brain-penetrant GLP-1/GIP agonist, engaged insulin signaling and neuroinflammation pathways in a small phase 1 study.

Early phase 1 findings showed that the PROTAC LRRK2 degrader ARV-102 was associated with improvements in saccadic hypometria and changes in CSF markers of endolysosomal function, neuroinflammation, synaptic integrity, and axonal guidance in participants with Parkinson disease.

The chairman of the Neurology Service Line at Baptist Health in Kentucky discussed PREVIEW trial findings for gefelorilimab in generalized myasthenia gravis, including efficacy, safety, and what the subcutaneous C5 inhibitor could offer patients if approved.

FDA approves once-daily oral tavapadon for Parkinson disease, a first-in-class D1/D5 partial agonist that improves motor function and ON time, with key safety warnings.

At a NeurologyLive Clinical Forum in Philadelphia, Jessica D. Schulte, MD, PhD, of NYU Grossman School of Medicine, discussed how earlier recognition and systemic therapy options are changing the treatment paradigm for patients with NF1-associated plexiform neurofibromas.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
12-Month Gluten-Free Diet Linked to Cognitive, Quality-of-Life Improvements in Parkinson Disease
2
LRRK2 Inhibitor BIIB122 Fails to Slow Early-Stage Parkinson Disease
3
GLP-1/GIP Agonist KP405 Shows Biomarker Signal in Parkinson Disease
4
Phase 1 Data Link ARV-102 LRRK2 Degradation to Oculomotor and CSF Biomarker Changes in Parkinson Disease
5

